A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

Kristeleit Rebecca; Shapiro Geoffrey I.; Burris Howard A.; Oza Amit M.; LoRusso Patricia; Patel Manish R.; Domchek Susan M.; Balmana Judith; Drew Yvette; Chen Lee-may; Safra Tamar; Montes Ana; Giordano Heidi; Maloney Lara; Goble Sandra; Isaacson Jeff; Xiao Jim; Borrow Jen; Rolfe Lindsey; Shapira-Frommer Ronnie

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

【24h】

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

机译：患有种系BRCA1 / 2型突变卵巢癌或其他实体瘤患者口腔PARP抑制剂Rucaparib的I-II期研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses.

机译：目的：Rucaparib是一种有效的口服，小分子PARP抑制剂。该阶段I-II研究是第一个评估单剂量口服Rucaparib的型研究。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2017年第15期|共12页
作者
Kristeleit Rebecca; Shapiro Geoffrey I.; Burris Howard A.; Oza Amit M.; LoRusso Patricia; Patel Manish R.; Domchek Susan M.; Balmana Judith; Drew Yvette; Chen Lee-may; Safra Tamar; Montes Ana; Giordano Heidi; Maloney Lara; Goble Sandra; Isaacson Jeff; Xiao Jim; Borrow Jen; Rolfe Lindsey; Shapira-Frommer Ronnie;
展开▼
作者单位

UCL Canc Inst Res Dept Oncol London England;

Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;

Tennessee Oncol PLLC Dept Med Oncol Sarah Cannon Res Inst Nashville TN USA;

Univ Hlth Network Princess Margaret Canc Ctr Dept Obstet &

Gynecol Toronto ON Canada;

Yale Univ Dept Med Oncol New Haven CT USA;

Sarah Cannon Res Inst Florida Canc Specialists Dept Med Oncol Sarasota FL USA;

Univ Penn Basser Ctr BRCA Dept Med Oncol Philadelphia PA 19104 USA;

Vall dHebron Univ Hosp Dept Med Oncol Barcelona Spain;

Northern Ctr Canc Care Dept Med Oncol Newcastle Upon Tyne Tyne &

Wear England;

Univ Calif San Francisco Dept Obstet Gynecol &

Reprod Sci Helen Diller Family Comprehens Canc Ctr;

Tel Aviv Sourasky Med Ctr Dept Oncol Tel Aviv Israel;

Guys Hosp Dept Med Oncol London England;

Clovis Oncol Inc Clin Sci Boulder CO USA;

Clovis Oncol Inc Clin Sci Boulder CO USA;

Clovis Oncol Inc Biostat Boulder CO USA;

Clovis Oncol Inc Stat &

Data Management Boulder CO USA;

Clovis Oncol Inc Clin Pharmacol &

Nonclin DMPK Boulder CO USA;

Clovis Oncol Inc Clin Dev Boulder CO USA;

Clovis Oncol Inc Clin &

Preclin Dev Boulder CO USA;

Sheba Med Ctr Dept Oncol Ramat Gan Israel;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors [J] . Kristeleit Rebecca, Shapiro Geoffrey I., Burris Howard A., Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第15期

机译：患有种系BRCA1 / 2型突变卵巢癌或其他实体瘤患者口腔PARP抑制剂Rucaparib的I-II期研究
2. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study [J] . Coleman Robert L., Sill Michael W., Bell-McGuinn Katherine, Gynecologic Oncology: An International Journal . 2015,第3期

机译：NRG肿瘤/妇科肿瘤小组研究对有效，高度选择性的PARP抑制剂veliparib进行II期评估，以治疗携带种系BRCA1或BRCA2突变的患者持续或复发的上皮性卵巢癌，输卵管或原发性腹膜癌
3. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer [J] . van der Biessen Diane A. J., Gietema Jourik A., de Jonge Maja J. A., Investigational new drugs. . 2018,第5期

机译：通过BRCA1 / 2突变和高级浆液卵巢，输卵管或原发性腹膜癌，对PARP抑制剂ABT-767进行PARP抑制剂ABT-767的研究
4. DESIGN AND SYNTHESIS OF NOVEL POLY ADP-RIBOSE POLYMERASE 1(PARP1)INHIBITORS FOR THE TREATMENT OF SOLID TUMORS [C] . J.Priyancy, D.P.Bhumika Conference on Drug Design and Discovery Technologies . 2020

机译：用于治疗实体肿瘤的新型聚ADP-核糖聚合酶1（PARP1）抑制剂的设计与合成
5. Gene therapy approaches for solid tumors: Ovarian carcinoma and bioreductive chemotherapy. [D] . Warrington, Kenneth Howard, Jr. 2000

机译：实体瘤的基因治疗方法：卵巢癌和生物还原化学疗法。
6. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian fallopian tube or primary peritoneal cancer [O] . Diane A. J. van der Biessen, Jourik A. Gietema, Maja J. A. de Jonge, -1

机译：PARP抑制剂ABT-767在具有BRCA1 / 2突变和高度浆液性卵巢癌输卵管癌或原发性腹膜癌的晚期实体瘤中的1期研究
7. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. [O] . Oza, AM, Tinker, AV, Oaknin, A, 2017

机译：paRp抑制剂rucaparib在高级别卵巢癌和种系或体细胞BRCa1或BRCa2突变患者中的抗肿瘤活性和安全性：来自研究10和aRIEL2的数据的综合分析。

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅